This segment encompasses BB Biotech AG's core business: investing in publicly traded biotechnology companies. The portfolio focuses on companies developing innovative medications and diagnostics, with a strong emphasis on companies in the United States and Western Europe. Investment decisions are based on fundamental analysis, evaluating financial statements, competitive landscapes, and R&D pipelines. The segment's performance is directly tied to the success of its portfolio companies, including their progress in clinical trials, regulatory approvals, and commercialization efforts. The company aims to provide capital to biotech companies to ensure and improve healthy lives and well-being. The segment's future growth depends on identifying and investing in promising biotech companies with strong growth potential and innovative technologies.